Coprocytobiology: on the nature of cellular elements from stools in the pathophysiology of colonic disease.
The gastrointestinal epithelium is known to undergo constant and rapid renewal resulting in millions of cells being shed into the fecal stream every day. The conventional wisdom was that these cells disintegrate upon exfoliation and will not survive the transit through the intestinal tract. In 1990, we (P.N.) made the discovery that a significant number of these cells remain intact and viable and that they can be isolated. The implications of this important discovery became apparent when we demonstrated that these cells are exclusively of colonic origin, are anatomically representative of the entire colon, and can be used for clinical investigations of disease processes. The term coprocytobiology (CCB) was coined to encompass the broad range of applications of this new technology. The somatic cell sampling and recovery (SCSR) process involves the isolation of exfoliated colonocytes from a small sample of stool ( approximately 1 g) collected and transported in a unique medium at ambient temperature, providing cells for the detection of a number of biomarkers of disease propensity. These exfoliated colonocytes express cytokeratins indicating epithelial lineage as well as colon-specific antigen. Over the years, the study of exfoliated colonocytes has provided striking new insights into the biology of colon cancer and inflammatory bowel disease, including detection of p53 gene mutations, reverse transcriptase polymerase chain reaction amplification, and identification of CD44 splice variants, neoplasia-associated specific binding of plant lectins, and expression of COX-2, the inducible form of cyclooxygenase. The functional diversity of cells isolated by SCSR is revealed by the demonstration of cell surface markers such as secretory component, IgA, and IgG on the one hand and the amplification and cloning of the human insulin receptor and the expression of the multidrug resistance gene mdr-1 on the other hand. This review portrays the immense potential of CCB as a powerful tool for investigating the pathophysiology of disease, identifying genetic variants in pharmacogenetics, assessment of mucosal immunity, and several other applications that use somatic cells.
Nair
Padmanabhan
P
Nutrition, Department of International Health, Johns Hopkins University, Baltimore, Maryland, USA. ppn@noninvasivetech.com
Lagerholm
Sara
S
Dutta
Sudhir
S
Shami
Samina
S
Davis
Kirk
K
Ma
Shuzhen
S
Malayeri
Mehran
M
D000951:Antigens, Neoplasm / Q000032:analysis; D003106:Colon / Q000166:cytology*; D003110:Colonic Neoplasms / Q000235:genetics / Q000503:physiopathology*; D005243:Feces / Q000166:cytology*; D015870:Gene Expression; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000235:genetics / Q000503:physiopathology*
D000951:Antigens, Neoplasm